GMO Launches GMO Systematic Investment Grade Credit ETF (INVG)
BOSTON--(BUSINESS WIRE)--GMO, a global investment manager known for its long-term, valuation-oriented strategies, today announced the launch of the GMO Systematic Investment Grade Credit ETF (INVG). This actively-managed ETF will employ a systematic, factor-based approach to identify and invest in attractive opportunities within the U.S. investment grade corporate credit market.
Building on GMO's expertise in quantitative investing and credit analysis, INVG will offer investors a differentiated solution for accessing investment grade corporate credit. The strategy is designed to pursue alpha through a blend of factors across value, quality, momentum, and issuer fundamentals, captured through proprietary fair value models, measures of changes in default risk, and momentum signals derived from credit and equity assets.
"The GMO Systematic Investment Grade Credit ETF represents our commitment to providing innovative and differentiated fixed-income solutions in the formats investors and their advisors want," said Scott Hayward, Chief Executive Officer of GMO.
The INVG ETF is designed for investors seeking investment grade corporate credit exposure managed in a systematic, risk-mitigated way.
'Investment grade corporate credit spans all major sectors and offers relatively lower default risk and offers investors access to higher quality corporate balance sheets across the global economy. INVG draws on GMO's quantitative capabilities with a systematic approach designed to maximize risk-adjusted returns,' said Joe Auth, Head of Developed Fixed Income.
The launch of INVG further expands GMO's lineup of ETFs, which focused on some of GMO's highest conviction current ideas and includes GMO U.S. Quality (QLTY), GMO International Quality (QLTI), GMO U.S. Value (GMOV), GMO International Value (GMOI), and GMO Beyond China (BCHI).
More information about GMO's ETFs can be found at: ETF Investing at GMO.
About GMO
Global investment manager GMO, established in 1977, brings together focused expertise within its investment teams, industry-leading research, and client solutions and service to advance clients' goals. Privately owned and renowned for conviction in a valuation-based, long-term investment philosophy, GMO serves sophisticated institutions, financial intermediaries, and families, and managed $65 billion as of March 31, 2025. The firm is headquartered in Boston, with offices in London, Sydney, Amsterdam, Singapore, and Tokyo (representative office). For more information, visit www.gmo.com.
Social Media:
LinkedIn: GMO
X: @GMOInsights
An investor should carefully consider the fund's investment objectives, risks, charges, and expenses before investing. This and other important information can be found in the fund's prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.
Risks associated with investing in the Fund may include: (1) Credit Risk; (2) Market Risk - Fixed Income Investments; (3) Management and Operational Risk. For a more complete discussion of these risks and others, please consult the Fund's Prospectus.
The GMO ETFs are distributed in the United States by Foreside Fund Services LLC. GMO and Foreside Fund Services LLC are not affiliated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
AI Enthusiasts Invited to ABBYY Developer Conference to Showcase Their Best Innovations Powering the Intelligent Enterprise
BENGALURU, India--(BUSINESS WIRE)--The AI Pulse by ABBYY Developer Conference returns to Bengaluru, India July 9-10, 2025, for the third annual hackathon competition. The free, two-day event will challenge assumptions about enterprise AI by showcasing how document AI and process intelligence are solving real business challenges with technical deep dives, innovative use cases, and collaborative sessions with an emphasis on measurable outcomes. What stood out most was how our partners combined ABBYY technology with other platforms to solve real business problems. That spirit of innovation and collaboration is what makes this event special. Share In addition to the hackathon, there will be a dedicated business track to equip enterprise leaders and center of excellence (CoE) architects with practical guidance on scaling automation, accelerating time to value through the ABBYY ecosystem, and building trust through responsible AI. Last year's competition saw projects ranging from invoice processing to onboarding workflows enhanced with generative AI. 'What stood out most was how our partners combined ABBYY technology with other platforms to solve real business problems. That spirit of innovation and collaboration is what makes this event special. This year, we're taking it a step further with dedicated tracks and extra recognition for the winners who truly push the boundaries with a customer-first approach,' commented Neil Murphy, Chief Revenue Officer at ABBYY. This year, prizes will be awarded for Best Overall App, Best Use of an ABBYY Product and Best Integration of 3 rd Party AI. Register for the competition at 'Since our first devcon three years ago, the level of sophistication and imagination using purpose-built AI for business-critical processes has surpassed all expectations. We're seeing challenges with document automation and process workflows eliminated, accuracy and time-to-value increase, and leadership teams more confident knowing they're using ABBYY AI,' commented Bruce Orcutt, Chief Marketing Officer at ABBYY. 'Whether you want to network, code or co-create, the ABBYY developer conference is where the future of AI and automation are shaped.' Don't miss the opportunity to explore ABBYY technology, learn new use cases in AI, or connect with peers and experts. Attendance to the AI Pulse by ABBYY Developer Conference is free, but seats are limited. Secure yours by registering today at or email DevCon_enquiries@ with any questions. Developers are also invited to attend the ABBYY Developers Discord community at About ABBYY ABBYY puts your information to work with purpose-built AI. We combine innovation and experience to transform data from business-critical documents into intelligent actionable outcomes in over 200 languages in real time. We are trusted by more than 10,000 companies globally, including many in the Fortune 500, to drive significant impact where it matters most: accelerating customer experience, operational excellence, and competitive advantage. ABBYY is a global company with headquarters in Austin, Texas and offices in 13 countries. For more information, visit and follow us on LinkedIn, Twitter, Facebook, and Instagram. ABBYY can either be a registered trademark or a trademark and can also be a logo, a company name (or part of it), or part of a product name of ABBYY group companies and may not be used without consent of its respective owners.
Yahoo
2 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
